Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to Tarsus' Third Quarter 2025 Financial Results Conference Call. As a reminder this call is being recorded.
Tarsus Pharmaceuticals Inc. (TARS)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deep Track Capital David Kroin | 3,004,034 | $245,970,304 | +1% | 4.39% |
| 2. | Paradigm Biocapital Advisors Senai Asefaw | 2,562,154 | $209,789,170 | -4% | 5.35% |
| 3. | Tang Capital Management Kevin C. Tang | 1,188,624 | $97,324,533 | -52% | 4.81% |
| 4. | Driehaus Capital Richard Driehaus | 1,172,427 | $95,998,323 | +14% | 0.65% |
| 5. | D E Shaw D. E. Shaw | 615,156 | $50,368,973 | +3% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.96 | 1,000 | $18,960.00 | 3,000 | 2023-12-15 | Filing | |
| $16.80 | 9,506 | $159,700.80 | 15,866 | 2023-08-15 | Filing | |
| $16.29 | 6,360 | $103,604.40 | 6,360 | 2022-09-14 | Filing | |
| $16.03 | 12,040 | $193,001.20 | 12,040 | 2022-09-14 | Filing | |
| $13.50 | 100,000 | $1,350,000.00 | 100,000 | 2022-05-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $82.93 | 893 | $74,056.49 | 23,393 | 2026-01-02 | Filing | |
| $81.90 | 835 | $68,386.50 | 24,286 | 2026-01-02 | Filing | |
| $80.71 | 8,122 | $655,526.62 | 25,121 | 2026-01-02 | Filing | |
| $80.09 | 5,715 | $457,714.35 | 33,243 | 2026-01-02 | Filing | |
| $83.54 | 557 | $46,531.78 | 857,991 | 2025-12-24 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,790,557 | $310,370,807 | 0.01% | |
| 2. | 3,335,320 | $273,096,002 | 2.74% | |
| 3. | 2,399,560 | $196,475,972 | 0% | |
| 4. | 2,230,069 | $182,598,052 | 0.11% | |
| 5. | 2,040,742 | $167,095,971 | 0.01% |
News See All
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to Tarsus Second Quarter 2025 Earnings Conference Call. As a reminder, this call is being recorded.
11 Best Breakout Stocks to Buy According to Analysts
Stock markets have been on edge in response to the US President's aggressive trade war that has resulted in trade tariffs aimed at settling the trade deficit.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q4 2024 Earnings Call Transcript
Operator: Good morning, and welcome to Tarsus Year End 2024 Financial Results Conference Call. As a reminder, this call is being recorded.
Billionaire Joseph Edelman's Top 10 Long-Term Stock Picks
Joseph Edelman is a renowned figure in the investment world, recognized for his expertise in biotechnology and healthcare investing.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2024 Earnings Call Transcript
Operator: Welcome to Tarsus' Third Quarter 2024 Financial Results Conference Call.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q2 2024 Earnings Call Transcript
Operator: Good afternoon. And welcome to the Tarsus’ Second Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q1 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to Tarsus's First Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded.
Aggressive Stock Portfolio: 13 Stocks Picked by Analysts
In this article, we will take a look at aggressive stock portfolio: 13 stocks picked by analysts.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q4 2023 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-1.31, expectations were $-1.37. Tarsus Pharmaceuticals, Inc.
Hedge Fund Resource Center Billionaire Hedge Funds
